The SciLifeLab Drug Discovery and Development platform (DDD) offers integrated drug discovery efforts to the Swedish academic research community. We offer industry standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept. The drug leads can be either a small molecule, a human antibody or new modality therapeutic. There are three ways to interact with DDD: DDDPROGRAM, DDDCOLLABORATIVE and DDDSERVICE. Services are offered in the following areas:
Importantly, the researcher/customer retains all rights and ownership during this process.
We encourage all academic researchers with an interest in turning their discoveries into cures for patients to contact us. For more information for how to start a project, please contact us via email@example.com
Six years from empty labs and without personnel to:
Our most recent project exit was Magnus Essand’s project on CAR-T cell therapy of glioblastoma. More about this project can be read here.
Another recent project exit was Susanne Lindquist’s project, in which we co-developed a biological anti-inflammatory drug candidate for which funding has been raised by Lipum AB to start Phase I clinical studies.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.